Presidio Management Group X. Ll Sells 4,000 Shares of eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) Stock

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR – Get Rating) major shareholder Presidio Management Group X. Ll sold 4,000 shares of the stock in a transaction that occurred on Monday, May 9th. The stock was sold at an average price of $2.54, for a total transaction of $10,160.00. Following the completion of the transaction, the insider now owns 140,137 shares in the company, valued at $355,947.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of eFFECTOR Therapeutics stock opened at $2.25 on Thursday. eFFECTOR Therapeutics, Inc. has a twelve month low of $2.03 and a twelve month high of $40.42. The company has a debt-to-equity ratio of 1.09, a quick ratio of 13.30 and a current ratio of 13.30. The business has a 50-day moving average price of $3.76 and a 200-day moving average price of $5.94.

eFFECTOR Therapeutics (NASDAQ:EFTR – Get Rating) last released its quarterly earnings data on Wednesday, March 16th. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.69. The firm had revenue of $0.31 million during the quarter. Sell-side analysts expect that eFFECTOR Therapeutics, Inc. will post -1.02 EPS for the current year.

EFTR has been the topic of several analyst reports. JMP Securities reiterated a “buy” rating and set a $8.00 target price on shares of eFFECTOR Therapeutics in a research report on Monday, April 11th. Stifel Nicolaus downgraded eFFECTOR Therapeutics from a “buy” rating to a “hold” rating and cut their price objective for the company from $20.00 to $6.20 in a research note on Tuesday, January 25th. Finally, Credit Suisse Group decreased their target price on shares of eFFECTOR Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a research note on Thursday, March 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, eFFECTOR Therapeutics currently has an average rating of “Buy” and an average price target of $19.64.

Several large investors have recently modified their holdings of EFTR. SR One Capital Management LP purchased a new stake in shares of eFFECTOR Therapeutics during the 4th quarter valued at about $56,487,000. Abingworth LLP purchased a new stake in eFFECTOR Therapeutics during the third quarter valued at approximately $67,027,000. Sectoral Asset Management Inc bought a new stake in shares of eFFECTOR Therapeutics in the 3rd quarter valued at approximately $40,503,000. OUP Management Co. LLC bought a new stake in shares of eFFECTOR Therapeutics in the 4th quarter valued at approximately $8,493,000. Finally, Parallel Advisors LLC bought a new position in shares of eFFECTOR Therapeutics during the 1st quarter valued at approximately $2,744,000. 51.71% of the stock is owned by institutional investors and hedge funds.

About eFFECTOR Therapeutics (Get Rating)

eFFECTOR Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer.

Featured Articles